Childhood cancer survival rates — by type

Across all types of childhood cancer combined, the five-year survival rate in well-resourced settings has risen dramatically over the past five decades — today, more children survive a cancer diagnosis than at any time in history. This improvement is the result of better diagnostic tools, more precise treatment protocols, and the growth of specialised paediatric oncology teams. That said, survival varies enormously between cancer types: some, like most forms of leukaemia, now have very high long-term cure rates, while others remain more difficult to treat. Your child's oncologist will discuss your specific situation rather than quoting a population average.

Acute lymphoblastic leukaemia (ALL), the most common childhood cancer, has one of the best outcomes of any cancer in children. In centres with access to modern risk-stratified chemotherapy, the large majority of children achieve long-term remission. Acute myeloid leukaemia (AML) is harder to treat and has a lower overall survival rate, though outcomes continue to improve with intensified protocols and stem cell transplant. Every child's leukaemia is different — age at diagnosis, white blood cell count at presentation, chromosome changes inside the cancer cells, and the speed of response to initial treatment all influence the final outlook.

Brain tumours are the most common solid tumour in children, and survival depends heavily on the specific tumour type, its location, and how completely it can be removed. Low-grade gliomas — by far the most common childhood brain tumour — generally have very favourable long-term outcomes with surgery alone or surgery combined with targeted therapy. High-grade tumours such as diffuse intrinsic pontine glioma (DIPG) remain among the most difficult cancers to treat anywhere in the body. Medulloblastoma, the most common malignant brain tumour in children, has substantially better outcomes in standard-risk patients treated at experienced centres. The tumour board review at diagnosis is critical for setting a realistic and individualised outlook.

There is a gap between survival rates reported in high-income countries and those seen in India, but this gap is narrowing. The main drivers are delayed diagnosis, treatment abandonment due to cost, and access to specialist paediatric oncology care. Children who reach a dedicated paediatric oncology team early — with a full diagnostic workup, a tumour board review, and consistent access to treatment — achieve outcomes that are competitive with international benchmarks. This is why the timing of your action matters. If you are concerned about a symptom or have just received a diagnosis, connecting with a specialist without delay is the single most important step.

Childhood lymphoma includes Hodgkin lymphoma and the various subtypes of non-Hodgkin lymphoma. Hodgkin lymphoma in children has some of the best outcomes of any cancer — the large majority of children treated in experienced centres achieve long-term remission, and many are cured with a relatively short course of chemotherapy with or without radiation. Non-Hodgkin lymphoma covers a range of subtypes; some, like Burkitt lymphoma and lymphoblastic lymphoma, are highly responsive to intensive short-course chemotherapy. Overall, lymphomas are among the most treatable childhood cancers when diagnosed and treated at the appropriate intensity.

Childhood cancers are biologically very different from one another. Some — like ALL and Hodgkin lymphoma — are driven by molecular pathways that respond strongly to chemotherapy. Others, like certain brain tumours and some solid tumours, are located in places that are difficult to reach surgically, or have biological features that make them less responsive to available treatments. Research over recent decades has mapped the genetic landscape of most childhood cancers, leading to new targeted medicines that have transformed some previously difficult diagnoses. This ongoing research means that the outlook for many cancer types continues to improve — an important reason to seek care at a centre that engages with current evidence-based protocols.